F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comShivalik Rasayan Ltd is an Indian pharmaceutical and chemical company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), agrochemicals, and specialty chemicals. Over the years, the company has developed a strong presence in both domestic and international markets. With its diversified product portfolio and consistent promoter backing, Shivalik Rasayan holds growth potential in the medium to long term.
When considering Shivalik Rasayan as an investment, it is not enough to only review current performance; long-term projections are crucial. This article reviews its historical performance, shareholding structure, and provides detailed share price targets from 2025 to 2030.
Based on the latest available data:
Open Price: ₹440.35
Previous Close: ₹436.80
Volume: 9,792
Value (Lacs): ₹42.71
VWAP: ₹440.99
Beta: 1.00 (average market volatility)
Market Cap: ₹687 Cr
Day’s High / Low: ₹446.30 / ₹434.85
UC Limit / LC Limit: ₹524.15 / ₹349.45
52-Week High / Low: ₹879.05 / ₹429.70
All-Time High / Low: ₹1,195.00 / ₹429.70
20D Avg Volume: 44,406
20D Avg Delivery (%): 40.32
Book Value Per Share: ₹322.12
Dividend Yield: 0.11%
Currently, the stock is trading near its 52-week low, indicating possible accumulation opportunities for long-term investors if fundamentals remain intact.
Retail & Others: 47.71%
Promoters: 47.37%
Foreign Institutions: 4.36%
Other Domestic Institutions: 0.56%
The nearly equal promoter and retail holding shows strong promoter confidence and active retail participation, while FII holdings add stability.
Pharma Growth: Demand for APIs and specialty chemicals globally.
Export Opportunities: Expanding global footprint in agrochemicals.
Government Policies: Make in India and PLI schemes for pharma.
Financial Stability: Strong book value but needs higher profitability.
Market Volatility: With a beta of 1.00, stock performance will largely track broader indices.
| Month | Price Target (₹) | Reason |
|---|---|---|
| January | 460 | Stable Q3 FY25 results |
| February | 470 | Retail accumulation |
| March | 485 | Union Budget pharma boost |
| April | 495 | Rising demand in chemicals |
| May | 510 | Export orders growth |
| June | 525 | Strong Q1 FY26 outlook |
| July | 540 | Positive FII sentiment |
| August | 555 | Robust quarterly results |
| September | 570 | Festive demand uptick |
| October | 585 | Policy support for pharma |
| November | 600 | R&D expansion |
| December | 620 | Year-end bullish trend |
| Month | Price Target (₹) | Reason |
|---|---|---|
| January | 635 | Sustained pharma momentum |
| February | 650 | Increasing institutional buying |
| March | 670 | Budget incentives for chemicals |
| April | 685 | Higher global demand |
| May | 700 | Improved debt profile |
| June | 720 | Strong quarterly performance |
| July | 740 | Expansion in API exports |
| August | 760 | Brokerage upgrades |
| September | 780 | Festive season demand |
| October | 800 | Supportive govt policies |
| November | 820 | Q2 FY27 performance |
| December | 850 | Year-end rally |
| Month | Price Target (₹) | Reason |
|---|---|---|
| January | 870 | Growing global recognition |
| February | 890 | Increased FII inflows |
| March | 910 | Budget-driven optimism |
| April | 930 | Expansion in specialty chemicals |
| May | 950 | Rising pharma demand |
| June | 975 | Stable financial results |
| July | 1,000 | Higher retail participation |
| August | 1,030 | Institutional buying |
| September | 1,060 | Festive demand |
| October | 1,090 | Renewable chemical expansion |
| November | 1,120 | Strong quarterly results |
| December | 1,150 | Bullish year-end |
| Month | Price Target (₹) | Reason |
|---|---|---|
| January | 1,180 | Strong FY27 earnings |
| February | 1,210 | Mutual fund participation |
| March | 1,240 | Budget pharma sector boost |
| April | 1,270 | Robust demand outlook |
| May | 1,300 | Expansion in agrochemicals |
| June | 1,330 | Improving margins |
| July | 1,360 | Higher financial stability |
| August | 1,390 | Strong earnings |
| September | 1,420 | Festive demand |
| October | 1,450 | Global chemical demand |
| November | 1,480 | Rural market growth |
| December | 1,520 | Year-end optimism |
| Month | Price Target (₹) | Reason |
|---|---|---|
| January | 1,550 | Positive FY28 outlook |
| February | 1,580 | Rising FII inflows |
| March | 1,610 | Budget support |
| April | 1,640 | Growth in export markets |
| May | 1,670 | Agrochemical expansion |
| June | 1,700 | Higher profitability |
| July | 1,740 | Institutional accumulation |
| August | 1,780 | Strong order pipeline |
| September | 1,820 | Festive demand |
| October | 1,860 | Policy-driven growth |
| November | 1,900 | Strong quarterly performance |
| December | 1,950 | Year-end rally |
| Month | Price Target (₹) | Reason |
|---|---|---|
| January | 1,980 | Robust FY29 results |
| February | 2,020 | Global pharma recognition |
| March | 2,060 | Budget-driven growth |
| April | 2,100 | Expanding API portfolio |
| May | 2,140 | Rising rural demand |
| June | 2,180 | Strong financial growth |
| July | 2,220 | Institutional buying |
| August | 2,260 | Strong Q1 FY31 results |
| September | 2,300 | Festive demand |
| October | 2,340 | Economic growth push |
| November | 2,380 | Global partnerships |
| December | 2,450 | Decade-end bullish close |
Regulatory Risks: Pharma and chemical industries face strict compliance norms.
Competition: High competition from domestic and global peers.
Raw Material Costs: Rising costs may pressure margins.
Market Volatility: Stock may mirror overall market swings.
Global Slowdown: Could reduce export opportunities.
Shivalik Rasayan Ltd has significant growth potential supported by its pharma and agrochemical businesses, balanced shareholding, and expansion opportunities in domestic and export markets.
Based on projections, the share price could reach ₹2,450 by 2030, provided the company maintains financial discipline, continues innovation, and leverages government incentives. Investors should monitor risks but the long-term outlook remains optimistic.
Register & Login